ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1PFE | PFIZER INC | Healthcare | $164.33B | 17.70% |
2CVS | CVS HEALTH CORP | Healthcare | $114.88B | 12.37% |
3ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 10.00% |
4CI | CIGNA GROUP | Healthcare | $78.07B | 8.41% |
5COR | CENCORA INC | Healthcare | $66.67B | 7.18% |
6HUM | HUMANA INC | Healthcare | $53.29B | 5.74% |
7GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 3.98% |
8CNC | CENTENE CORP | Healthcare | $34.79B | 3.75% |
9VTRS | VIATRIS INC | Healthcare | $23.70B | 2.55% |
10THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 2.46% |
11ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 2.13% |
12SOLV | SOLVENTUM CORP | Healthcare | $15.07B | 1.62% |
13BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 1.43% |
14ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 1.43% |
15COO | COOPER COMPANIES INC | Healthcare | $11.83B | 1.27% |
16UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 1.20% |
17BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 1.18% |
18MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 1.18% |
19DVA | DAVITA INC | Healthcare | $10.95B | 1.18% |
20BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 1.07% |
21OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 1.07% |
22HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 1.03% |
23BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.81% |
24TFX | TELEFLEX INC | Healthcare | $6.07B | 0.65% |
25WAY | WAYSTAR HOLDING CORP | Healthcare | $5.41B | 0.58% |
26NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.43% |
27OGN | ORGANON & CO | Healthcare | $3.65B | 0.39% |
28ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.38% |
29SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.37% |
30BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.33% |
31ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.27% |
32NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.26% |
33PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.24% |
34PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.23% |
35BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.23% |
36FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.21% |
37AZTA | AZENTA INC | Healthcare | $1.92B | 0.21% |
38TRLV | TRULIEVE CANNABIS CORP | Healthcare | $1.90B | 0.20% |
39XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.20% |
40ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.19% |
41SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.18% |
42SNDA | SONIDA SENIOR LIVING INC | Healthcare | $1.63B | 0.18% |
43ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.17% |
44OMCL | OMNICELL INC | Healthcare | $1.61B | 0.17% |
45ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.17% |
46TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.17% |
47CNMD | CONMED CORP | Healthcare | $1.50B | 0.16% |
48AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.16% |
49PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.16% |
50LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.44B | 0.15% |
51GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.15% |
52INVA | INNOVIVA INC | Healthcare | $1.35B | 0.15% |
53AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.13% |
54TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.13% |
55IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.12% |
56AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.12% |
57AORT | ARTIVION INC | Healthcare | $947M | 0.10% |
58COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.08% |
59VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.08% |
60GMRS | GMR SOLUTIONS INC | Healthcare | $754M | 0.08% |
61QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.08% |
62JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.08% |
63FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.07% |
64DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.07% |
65MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.06% |
66CTEV | CLARITEV CORP | Healthcare | $459M | 0.05% |
67ARVN | ARVINAS INC | Healthcare | $450M | 0.05% |
68AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.05% |
69EMBC | EMBECTA CORP | Healthcare | $364M | 0.04% |
70MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.04% |
71EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.04% |
72EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.03% |
73EVMN | EVOMMUNE INC | Healthcare | $291M | 0.03% |
74OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.03% |
75QTTB | Q32 BIO INC | Healthcare | $264M | 0.03% |
76BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.03% |
77LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.03% |
78RXST | RXSIGHT INC | Healthcare | $226M | 0.02% |
79AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.02% |
80TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.02% |
81KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.02% |
82RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.02% |
83ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.02% |
84OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.02% |
85STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.02% |
86INGN | INOGEN INC | Healthcare | $146M | 0.02% |
87RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.01% |
88IMUX | IMMUNIC INC | Healthcare | $106M | 0.01% |
89PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
90RLYB | RALLYBIO CORP | Healthcare | $84M | 0.01% |
91VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.01% |
92XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.01% |
93ELOX | ELOXX PHARMACEUTICALS INC | Healthcare | $52M | 0.01% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $928.60B. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 97% toward Large, 42% toward Growth. +9% unclassified (23 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 93 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 93 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 17%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 37.7% | 16.5% |
| 3 yearsp.a. | 19.3% | -6.3% |
| 5 yearsp.a. | 12.0% | -2.9% |
| 10 yearsp.a. | 12.0% | -5.9% |
| Since inceptionp.a. | 12.8% | 1.3% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 37.8% | 14.1% |
| 2025 | 20.5% | -11.0% |
| 2024 | -3.5% | -17.7% |
| 2023 | -2.8% | -25.3% |
| 2022 | 1.5% | 23.8% |
| 2021 | 24.7% | 19.7% |
| 2020 | 10.0% | -20.0% |
| 2019 | 26.2% | -3.2% |
| 2018 | -0.6% | -8.4% |
| 2017 | 14.9% | -20.0% |
| 2016 | -14.1% | 0.8% |
| 2015 | 13.4% | 5.1% |
| 2014 | 25.0% | -5.1% |
| 2013 | 48.1% | 4.3% |
| 2012 | 15.4% | -7.5% |
| 2011 | 14.5% | 5.5% |
| 2010 | 9.8% | 2.5% |
| 2009 | 44.1% | 26.8% |
| 2008 | -39.4% | -31.7% |
| 2007 | 10.1% | 4.2% |
| 2006 | 4.8% | 5.3% |
| 2005 | 26.7% | 5.5% |
| 2004 | 25.7% | 18.1% |
| 2003 | 47.2% | 23.8% |
| 2002 | -17.6% | 3.3% |
| 2001 | 14.3% | 47.0% |
| 2000 | 76.1% | 35.8% |
| 1999 | -9.8% | -12.8% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare AM Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a AM signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.